Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study
Abstract. Background. Renal cell carcinoma (RCC) has traditionally been considered to be radioresistant. Response rates are believed to be improved by a high dose of stereotactic body radiotherapy (SBRT). A retrospective analysis was conducted of patients treated with SBRT for metastatic disease fro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2025-05-01
|
| Series: | Current Urology |
| Online Access: | http://journals.lww.com/10.1097/CU9.0000000000000191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849310506169401344 |
|---|---|
| author | Hanan Rida Hind Zaine Hassan Jouhadi Abdellatif Benider Hamza Samlali Redouane Samlali |
| author_facet | Hanan Rida Hind Zaine Hassan Jouhadi Abdellatif Benider Hamza Samlali Redouane Samlali |
| author_sort | Hanan Rida |
| collection | DOAJ |
| description | Abstract. Background. Renal cell carcinoma (RCC) has traditionally been considered to be radioresistant. Response rates are believed to be improved by a high dose of stereotactic body radiotherapy (SBRT). A retrospective analysis was conducted of patients treated with SBRT for metastatic disease from RCC.
Material and methods. We reviewed records from 20 patients who underwent SBRT for a total of 30 RCC metastases from 2015 to 2020. Patients were included who had a confirmed primary RCC and radiographic evidence of metastasis, either synchronous or metachronous. The most common SBRT fractionation was 30 Gy in 3 fractions.
Results. Median age was 60 years (range, 40–77 years) and 60% were male. After a median follow-up of 18 months (range, 3–36 months), overall survival was estimated to be 85% and 70%, at 1 and 2 years, respectively, and local control at 2 years was 83.33%. Only 5 patients had documented progression of disease, all of whom received biologically effective dose inferior to 100 Gy, and no patients treated with a higher biologically effective dose had disease, which progressed. The most common acute toxicity was grade 1 fatigue (20%). No grade 3 or higher acute toxicity occurred.
Conclusions. Treatment with SBRT in patients with RCC metastases yielded a high local control rate, promising survival rate, and low toxicity. |
| format | Article |
| id | doaj-art-47fc79703b5b458aad9f4697da3c692f |
| institution | Kabale University |
| issn | 1661-7649 1661-7657 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Current Urology |
| spelling | doaj-art-47fc79703b5b458aad9f4697da3c692f2025-08-20T03:53:42ZengWolters Kluwer HealthCurrent Urology1661-76491661-76572025-05-0119318719110.1097/CU9.0000000000000191202505000-00006Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective studyHanan Rida0Hind Zaine1Hassan Jouhadi2Abdellatif Benider3Hamza Samlali4Redouane Samlali5a Department of Oncology-Radiotherapy, University Hospital Ibn Roch, Casablanca, Moroccoa Department of Oncology-Radiotherapy, University Hospital Ibn Roch, Casablanca, Moroccoa Department of Oncology-Radiotherapy, University Hospital Ibn Roch, Casablanca, Moroccoa Department of Oncology-Radiotherapy, University Hospital Ibn Roch, Casablanca, Moroccob Clinique d’oncologie le Littoral, Casablanca, Moroccob Clinique d’oncologie le Littoral, Casablanca, MoroccoAbstract. Background. Renal cell carcinoma (RCC) has traditionally been considered to be radioresistant. Response rates are believed to be improved by a high dose of stereotactic body radiotherapy (SBRT). A retrospective analysis was conducted of patients treated with SBRT for metastatic disease from RCC. Material and methods. We reviewed records from 20 patients who underwent SBRT for a total of 30 RCC metastases from 2015 to 2020. Patients were included who had a confirmed primary RCC and radiographic evidence of metastasis, either synchronous or metachronous. The most common SBRT fractionation was 30 Gy in 3 fractions. Results. Median age was 60 years (range, 40–77 years) and 60% were male. After a median follow-up of 18 months (range, 3–36 months), overall survival was estimated to be 85% and 70%, at 1 and 2 years, respectively, and local control at 2 years was 83.33%. Only 5 patients had documented progression of disease, all of whom received biologically effective dose inferior to 100 Gy, and no patients treated with a higher biologically effective dose had disease, which progressed. The most common acute toxicity was grade 1 fatigue (20%). No grade 3 or higher acute toxicity occurred. Conclusions. Treatment with SBRT in patients with RCC metastases yielded a high local control rate, promising survival rate, and low toxicity.http://journals.lww.com/10.1097/CU9.0000000000000191 |
| spellingShingle | Hanan Rida Hind Zaine Hassan Jouhadi Abdellatif Benider Hamza Samlali Redouane Samlali Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study Current Urology |
| title | Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study |
| title_full | Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study |
| title_fullStr | Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study |
| title_full_unstemmed | Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study |
| title_short | Stereotactic body irradiation for metastasis from renal carcinoma: A retrospective study |
| title_sort | stereotactic body irradiation for metastasis from renal carcinoma a retrospective study |
| url | http://journals.lww.com/10.1097/CU9.0000000000000191 |
| work_keys_str_mv | AT hananrida stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy AT hindzaine stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy AT hassanjouhadi stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy AT abdellatifbenider stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy AT hamzasamlali stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy AT redouanesamlali stereotacticbodyirradiationformetastasisfromrenalcarcinomaaretrospectivestudy |